However, the knockdown of ANGPT2 by the CRISPR/Cas system significantly suppressed the HCC progression, not only by decreasing the level of exosomal ANGPT2 but also by inhibiting EMT activation, suggesting that the CRISPR/Cas system is a promising trend of HCC therapy by blocking ANGPT2. Here, ANGPT2 is linked to hepatocellular carcinoma.